Silk Road Medical Inc (NASDAQ:SILK) CEO Erica J. Rogers sold 20,044 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $47.43, for a total value of $950,686.92. Following the transaction, the chief executive officer now directly owns 117,590 shares in the company, valued at approximately $5,577,293.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of SILK opened at $47.11 on Friday. The company’s 50-day moving average is $43.26 and its 200-day moving average is $38.26. Silk Road Medical Inc has a fifty-two week low of $27.83 and a fifty-two week high of $51.50. The company has a debt-to-equity ratio of 0.58, a current ratio of 10.61 and a quick ratio of 9.86.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new stake in Silk Road Medical during the fourth quarter worth about $293,000. Bank of America Corp DE increased its holdings in Silk Road Medical by 1,357.6% in the 4th quarter. Bank of America Corp DE now owns 105,736 shares of the company’s stock valued at $4,270,000 after buying an additional 98,482 shares during the period. UBS Asset Management Americas Inc. bought a new position in Silk Road Medical in the 4th quarter valued at about $238,000. Bank of New York Mellon Corp raised its position in shares of Silk Road Medical by 76.8% in the 4th quarter. Bank of New York Mellon Corp now owns 82,302 shares of the company’s stock valued at $3,324,000 after buying an additional 35,754 shares in the last quarter. Finally, Fred Alger Management LLC raised its position in shares of Silk Road Medical by 15.4% in the 4th quarter. Fred Alger Management LLC now owns 9,233 shares of the company’s stock valued at $373,000 after buying an additional 1,233 shares in the last quarter. Institutional investors own 87.83% of the company’s stock.
Several research firms have issued reports on SILK. BidaskClub lowered Silk Road Medical from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine downgraded Silk Road Medical from a “buy” rating to a “hold” rating in a research note on Saturday, December 21st. Finally, Zacks Investment Research lowered Silk Road Medical from a “hold” rating to a “sell” rating in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $43.50.
Silk Road Medical Company Profile
Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.
Featured Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.